Tonelli believes that those with a family history of the illness will ... successfully inhibit FGFR2, plus the EGFR protein — it is known to accelerate pancreatic cancer — she observed slower ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

EGFR and HER3 are members of the human epidermal growth factor receptor (HER) family and are validated ... Somatostatin receptor 2 (SSTR2) is a G protein-coupled receptor (GPCR) that is ...

C-Met is a cell surface protein that is overexpressed in approximately 25% of patients with advanced epidermal growth factor receptor (EGFR) wild-type, nonsquamous NSCLC, driving tumor progression.

Epidermal growth factor receptor (EGFR), when overactive or overexpressed, may lead to tumor growth and spread, and is thus a robust target for therapy.

A new study from Cold Spring Harbor Laboratory, published in Cancer Research, shows that inhibiting the FGFR2 and EGFR proteins in pancreatic cells can delay or even prevent tumor formation.